USPTO and Congress bash India over the Nexavar compulsory license
On June 27, 2012, Teresa Stanek Rea, the Deputy Under Secretary of Commerce for Intellectual Property and the Deputy Director of the United States Patent and Trademark Office (USPTO), testified at a hearing on: “International IP Enforcement: Protecting Patents, Trade Secrets and Market Access”, before the US House of Representatives, Judicary Committee, Subcommittee on Intellectual Property, Competition, and the Continue Reading
Nexavar compulsory license case in India
Teresa Stanek Rea, Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the United States Patent and Trademark Office (USPTO), testifying at a June 27, 2012 hearing on: “International IP Enforcement: Protecting Patents, Trade Secrets and Market… Continue Reading
The European Orphan Works Directive: a missed opportunity?
Earlier this month, the European Parliament and the European Commission released a new compromise text on orphan works.
The Compromise Text is available here:
http://register.consilium.europa.eu/pdf/en/12/st10/st10953.en12.pdf
KEI sees the text as a step backwards for access to knowledge. The proposed directive makes far too many compromises, is too limited in terms of the beneficiaries and uses of works, and creates complicated, burdensome and costly procedures and record keeping requirements.
Background on earlier EU consultations
KEI letter to USTR regarding TPPA copyright provisions
The governments of Brunei, Chile, New Zealand, Singapore, Australia, Malaysia, Peru, Vietnam and the United States are negotiating a multilateral free trade agreement known as the Trans-Pacific Partnership Agreement (TPP). The negotiations are being conducted with considerable secrecy, even though they address many issues of great interest to the general public. The Agreement will cover many topics, including intellectual property rights, the pricing of pharmaceutical drugs, and the rights of investors to sue states over policies and actions that impact their investments. Continue Reading
AUD $2 million Australia-WIPO MOU targets TIGAR, neglected diseases, developing IP systems and technology transfer
On 15 June 2012, the World Intellectual Property Organization and the Australian Permanent Mission to the World Trade Organization signed an agreement and released a joint communiqué “detailing how an AUD$2 million Australian contribution would assist least-developed and developing countries improve their intellectual property systems”.
Applauding WIPO Webcast and Video-on-Demand
Clearly WIPO could teach a few things to many agencies –other UN bodies but also for example the office of the US Trade Representatives– regarding transparency and accessibility for all stakeholders.
Update: Global Fund responds to Report on William Steiger
The Global Fund just sent an email, which says that “your website which inaccurately reports that Mr Steiger will run VPP.” Here is the Global Fund email:
From: Andrew Hurst
Date: June 20, 2012 5:36:49 PM GMT+02:00
To: Thirukumaran BalasubramaniamSubject: RE: Question on the Global Fund’s Voluntary Pooled Procurement? Dear Thiru
Further to our conversation this week, here is our statement:
2 KEI and UAEM file brief as amici curiae in BRCA gene patent case
On Friday, June 15, 2012, Knowledge Ecology International (KEI) and Universities Allied for Essential Medicines (UAEM) filed as amici curiae in the case Association for Molecular Pathology, et. al. v. United States Patent and Trademark Office, et. al which is currently being heard before the Court of Appeals for the Federal Circuit. The full brief is available for download here.
The language in S. 3187, calling for National Academies evaluation of Medical Innovation inducement prizes
S.3187 Food and Drug Administration Safety and Innovation Act (Engrossed in Senate [Passed Senate] – ES)SEC. 906. INDEPENDENT STUDY ON MEDICAL INNOVATION INDUCEMENT MODEL.